At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,028 enrolled
Drug / intervention
RSVpreF (Group 1) +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS
In Brief
A Phase 3 clinical trial evaluating RSVpreF (Group 1), RSVpreF (Group 2), and 2 other interventions for RSV. Completed, enrolled 1,028 participants across 18 sites.
Detailed Summary
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRSV
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedOct 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedOct 27, 2021
Enrollment StartOct 21, 2021
Primary CompletionApr 4, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.7 years ago
Interventions
RSVpreF (Group 1)biological
RSV vaccine (RSVpreF)
RSVpreF (Group 2)biological
RSV vaccine (RSVpreF)
RSVpreF (Group 3)biological
RSV vaccine (RSVpreF)
Placebobiological
Placebo